Navigation Links
Opportunity Exists in the U.S. for Novel Agents in Crohn's Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
Date:12/10/2013

BURLINGTON, Mass., Dec. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that lack of initial response or waning efficacy over time are the main reasons that patients discontinue treatment with leading anti-TNFs, Janssen's Remicade and AbbVie's Humira in Crohn's disease (CD) and ulcerative colitis (UC), according to surveyed gastroenterologists. Furthermore, gastroenterologists estimate that one-fifth of their patients taking these agents express dissatisfaction and are eager to switch to an alternative therapy that can achieve higher rates of clinical remission and maintain clinical remission. If the following emerging therapies with novel mechanisms of action—Takeda's CAM inhibitor vedolizumab for CD and UC, Janssen's IL-12/IL-23 inhibitor Stelara for CD and Pfizer's oral Jak inhibitor Xeljanz for UC—can meet physicians' expectations about efficacy, such agents should be well positioned. However, because cost-related issues such as a lower list price than anti-TNFs are cited by managed care organizations (MCOs) as key drivers for favorable formulary inclusion, such therapies will likely face challenges obtaining preferential coverage since many plans already cover Remicade and Humira on tier 2.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The U.S. Physician & Payer Forum report entitled Promising Pipelines for Crohn's Disease and Ulcerative Colitis: Payer and Prescriber Receptivity as the Market for Premium-Priced Therapies Expands Beyond the TNF-alpha Inhibitors finds that, among all emerging therapies, the greatest opportunity exists for vedolizumab's use in CD, with over two-thirds of gastroenterologists expecting to prescribe th
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sphere Fluidics: Expanding Executive Team for Growth of New Market Opportunity
2. New Primer Co-Authored by Novation Describes Potential Impact of Biosimilars on Pharmacy Practice; Opportunity for Hospitals to Manage Drug Expenditures
3. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
4. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
5. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
6. OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
7. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
8. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
9. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
10. Post-ACA Implementation Brings Opportunity And Uncertainty To Pharmaceutical Companies Looking To Capture Growth In New Places
11. Surveys Reveal Opportunity for Medical Community to Fully Embrace Biomarker Testing in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 ... study Stationary Oxygen Concentrators Market Shares, Strategy, ... poised to achieve continuing growth as the aging population ... and other respiratory conditions where oxygen is able to ... manner. Portable devices have become affordable and support a ...
(Date:7/1/2015)... OncoSec Medical Inc. ("OncoSec") (Nasdaq: ONCS ), a company ... President Punit Dhillon will ring The Nasdaq Opening ... Stock Market at 9:30 am ET on July 7, 2015 ... .   "On behalf of all of ... open the Nasdaq to celebrate OncoSec,s listing on this leading ...
(Date:7/1/2015)... -- New exchange plan enrollees spent less on medications ... same time a year ago, according to the third ... Exchange Pulse™ report, released today. When compared ... new exchange plan enrollees who used at least one ... of 2015. However, when evaluating exchange plan medication trends ...
Breaking Medicine Technology:Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 2OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 2Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 4Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 5
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading integrated ... release its third quarter 2011 financial results on Tuesday, November ... markets.  The Company will also host a conference call and ... to discuss its financial results and provide an update on ...
... RANCHO CORDOVA, Calif., Sept. 23, 2011 AMPAC Fine ... Corporation (Nasdaq®: APFC), announced that Terence "Terry" Vollrath has ... very pleased to have an accomplished leader like Terry ... Aslam Malik, President of AFC.   Vollrath, ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings 2AMPAC Fine Chemicals Names Terry Vollrath Vice President of Operations 2AMPAC Fine Chemicals Names Terry Vollrath Vice President of Operations 3
(Date:7/1/2015)... ... ... Did you know that infertility in men is more common than couples ... Center of Texas (AFCT) would like to talk about some natural ways to increase ... be a “woman’s issue,” male fertility factors can play a role in about 40% ...
(Date:7/1/2015)... Humble, TX (PRWEB) , ... July 01, 2015 , ... ... also another symptom found in a significant number of women: leg pain. Northeast Houston ... , Leg pain, a symptom of venous reflux disease, is underdiagnosed and often ...
(Date:7/1/2015)... ... July 01, 2015 , ... Trevor L. Williams, DMD ... Florida and continued at USF earning a Master’s degree in Microbiology. He graduated from ... of the American Dental Association, the Florida Dental Association and the Academy of General ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... software products, announced today that it has received trademark protection for its SensorInsight® ... detailed analysis of data from multiple sources providing an environment where users can ...
(Date:7/1/2015)... ... 01, 2015 , ... A Priority Setting Partnership put in ... list they hope will guide future mesothelioma research. Surviving Mesothelioma has just posted ... , More than 450 mesothelioma patients, caregivers, and healthcare professionals answer the ...
Breaking Medicine News(10 mins):Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2
... -- Patients in hospitals where nurses work long hours are ... researchers have found. In most U.S. hospitals, nurses work ... due to nationwide nursing shortages, the authors of the new ... of the compressed nature of the work week, the long ...
... LOS ANGELES (January 19, 2011) Following a competitive ... Research for the Department of Pediatrics, Children,s Hospital Los ... the hospital to become part of the Autism Treatment ... The ATN is supported by Autism Speaks, which ...
... humans, has no known cure or vaccine. But a new ... a family of small molecules which appear to bind to ... into human cells. The results are to be published ... now online. Previous studies have shown that small molecules ...
... scientists have discovered that cells lining the blood vessels ... cells from invading other tissues, a finding that could ... Elazer Edelman, professor in the MIT-Harvard Division of Health ... adjacent to a patient,s tumor could shrink a tumor ...
... conducted at the Oregon National Primate Research Center at Oregon ... contraceptives cause weight gain appears to be false. The results ... next month,s edition of the journal Human Reproduction . ... contraceptives and the possibility that they may cause weight gain ...
... WEDNESDAY, Jan. 19 (HealthDay News) -- Many U.S. transplant ... trying to develop new safeguards that would protect and ... one-third of transplant surgeons in the nation "overreacted" to ... contracted HIV after receiving organs from a single donor ...
Cached Medicine News:Health News:Nurses' Long Shifts May Put Hospital Patients at Risk: Study 2Health News:Children's Hospital Los Angeles joins Autism Treatment Network 2Health News:Small molecules may prevent ebola infection 2Health News:MIT scientists discover cancer-fighting role for cells 2Health News:MIT scientists discover cancer-fighting role for cells 3Health News:MIT scientists discover cancer-fighting role for cells 4Health News:Do birth control pills cause weight gain? New research says no 2
... CELL-DYN SMS consistently produces high-quality blood films. ... blood films every time, eliminating the need ... high or low hematocrit values. In the ... identifies the sample, and aspirates only 200L. ...
... FS laser introduces new high precision femtosecond ... have the opportunity to offer their patients ... microkeratome for creating the corneal flap. ... and proprietary IntraLASIK software, surgeons may avoid ...
... simple, effective screening test which is used to ... levels which are often a warning sign of ... which requires a single drop of blood obtained ... shown in clinical trials to be 94 to ...
The Lifestream Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program. At a later date, you can purchase the other components...
Medicine Products: